Home » Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: Insights From the GUARDIANS Multicenter Cohort – OncoDaily

Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: Insights From the GUARDIANS Multicenter Cohort – OncoDaily

by Oncodaily - Oncology News, Insights, Stories | Dec 1, 2025 | Articles | 0 Comments